Table 1.
Characteristics of patients with breast cancer
| All patients | DR | No DR | χ2 | P | |
|---|---|---|---|---|---|
| N(%) | 342 (100%) | 256 (74.9%) | 86 (25.1%) | ||
| Age (mean ± SD, range, years) |
46.65 ± 10.00 (19–77) |
45.80 ± 10.10 (19–77) |
49.19 ± 9.30 (28–69) |
- | 0.006 |
| ≤ 46 | 169 (49.4%) | 135 (39.5%) | 34 (9.9%) | ||
| > 46 | 173 (50.6%) | 121 (35.4%) | 52 (15.2%) | ||
| Primary site | 0.060 | 0.806 | |||
| Left | 183 (53.5%) | 136 (39.8%) | 47 (13.7%) | ||
| Right | 159 (46.5%) | 120 (35.1%) | 39 (11.4%) | ||
| Menopause | 1.243 | 0.265 | |||
| No | 216 (63.2%) | 166 (48.5%) | 50 (14.6%) | ||
| Yes | 126 (36.8%) | 90 (26.3%) | 36 (10.5%) | ||
| Histological type | 6.967 | 0.008 | |||
| Ductal | 218 (63.7%) | 153 (44.7%) | 65 (19.0%) | ||
| Others | 124(36.3%) | 103 (30.1%) | 21 (6.1%) | ||
| Tumor size | 49.839 | 0.000 | |||
| ≤ 2 cm | 102 (29.8%) | 51 (14.9%) | 51 (14.9%) | ||
| 2–5 cm | 151 (44.2%) | 122 (35.7%) | 29 (8.5%) | ||
| ≥ 5 cm | 83 (24.3%) | 77 (22.5%) | 6 (1.8%) | ||
| N stage | 80.151 | 0.000 | |||
| N0 | 109 (31.9%) | 50 (14.6%) | 59 (17.3%) | ||
| N1 | 77 (22.5%) | 59 (17.3%) | 18 (5.3%) | ||
| N2 | 63 (18.4%) | 58 (17.0%) | 5 (1.5%) | ||
| N3 | 93 (27.2%) | 89 (26.0%) | 4 (1.2%) | ||
| Grading | 33.202 | 0.000a | |||
| G1 | 15 (4.4%) | 12 (3.5%) | 3 (0.9%) | ||
| G2 | 143 (41.8%) | 83 (24.3%) | 60 (17.5%) | ||
| G3 | 163 (47.7%) | 151 (44.2%) | 12 (3.5%) | ||
| G4 | 19 (5.5%) | 8 (2.3%) | 11 (3.2%) | ||
| Molecular subtype | 40.258 | 0.000b | |||
| Luminal A | 23 (6.7%) | 7 (2.0%) | 16 (4.7%) | ||
| Luminal B HER2-neg | 149 (43.6%) | 111 (32.5%) | 38 (11.1%) | ||
| Luminal B HER2-pos | 29 (8.5%) | 25 (7.3%) | 4 (1.2%) | ||
| HER2-pos | 66 (19.3%) | 59 (17.3%) | 7 (2.0%) | ||
| Triple negative | 62 (18.1%) | 54 (15.8%) | 8 (2.3%) | ||
| Unknown | 13 (3.8%) | - | 13 (3.8%) | ||
| Treatment strategy | 27.071 | 0.000c | |||
| Breast conserving | 20 (5.8%) | 6 (1.8%) | 14 (4.1%) | ||
| Mastectomy | 252 (73.7%) | 195 (57.0%) | 57 (16.7%) | ||
| Chemotherapy | 64 (18.7%) | 55 (16.1%) | 9 (2.6%) | ||
| Unknown | 6 (1.8%) | - | 6 (1.8%) |
Data are presented as numbers (percentages). The P value represents the result of statistical significance testing with χ2 test (or by a two-tailed Student’s t-test for age) for comparison between patients with disease recurrence (DR) and without relapse (no DR)
aχ2 test performed on classified groups (G1/G2 vs. G3/G4)
bχ2 test performed on classified groups (Luminal A/ Luminal B HER2-neg/ Luminal B HER2-pos/ HER2-pos/ Triple negative)
cχ2 test performed on classified groups (breast conserving/ mastectomy/ chemotherapy). Lymph node staging (N stage) was based on the eighth edition of AJCC